Skip to main content
Premium Trial:

Request an Annual Quote

Exagen Raises $7M in Series B Private-Equity Round

NEW YORK, June 28 (GenomeWeb News) -  Exagen Diagnostics has raised $7 million in a Series B round of private-equity financing, the company said today. 


Tullis-Dickerson led the round, while vSpring Capital and Wasatch Venture Fund participated. As GenomeWeb News has reported, Exagen completed a $5.7 million Series A round in early 2004 with the same group of investors.


Exagen, based in Albuquerque, NM, uses computational methods to develop genomic markers. It is currently validating prognostic marker sets for breast cancer and hepatitis C that aim to guide treatment decisions.


The company said its first test will be the Key2 Breast Cancer Prognosis panel, which is designed to detect changes in DNA copy number in both hormone receptor-positive and hormone receptor-negative tumors.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.